NDT Advance Access originally published online on October 4, 2005
Nephrology Dialysis Transplantation 2005 20(12):2613-2619; doi:10.1093/ndt/gfi166
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© The Author [2005]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org
Editorial Review
Complement and the kidney: What the nephrologist needs to know in 2006?
Department of Nephrology, Leiden University Medical Center, The Netherlands
Correspondence and offprint requests to: Stefan Berger, Department of Nephrology, C3-P25, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands.
| The first 150 words of the full text of this article appear below. |
| Introduction |
|---|
The renewed appreciation of the role of the complement system as a mediator and marker of renal damage has led to numerous recent investigations in the field of complement and renal disease. The aims of the present review are:
- to recapitulate the pathways of complement activation with an emphasis on the more recently described lectin pathway of complement activation
- to discuss some of the new data on the role of complement in renal disease and,
- to briefly provide information about new diagnostic techniques in the field of complement,
- to discuss some of the new data on the role of complement in renal disease and,
| Pathways of complement activation |
|---|
The complement system is not only an important component of the innate immune system but it also plays an essential role in the initiation and control of the adaptive immune response. The three pathways of complement activation converge at the level of C3. Activation of C3 leads to the formation of the membrane attack complex (MAC) on complement-activating surfaces (Figure 1
| Role of complement in renal disease |
|---|
Glomerulonephritis
Lupus nephritis
IgA-nephropathy
Ischaemia/reperfusion damage
Kidney transplantation
Atypical haemolytic-uraemic syndrome
Progression of chronic renal disease
Diabetic nephropathy
| Measurement of complement pathway activity: methods and indications |
|---|
| Inhibitors of complement activation in the treatment of renal disease |
|---|
| Concluding remarks |
|---|
This article has been cited by other articles:
![]() |
P. Boor, A. Konieczny, L. Villa, A.-L. Schult, E. Bucher, S. Rong, U. Kunter, C. R.C. van Roeyen, T. Polakowski, H. Hawlisch, et al. Complement C5 Mediates Experimental Tubulointerstitial Fibrosis J. Am. Soc. Nephrol., May 1, 2007; 18(5): 1508 - 1515. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. L. Zhang, S. K. Malek, T. M. Blasick, J. R. Pennington, K. K. Masker, M. Lun, and S. Potdar C4d Positivity Is Often Associated with Acute Cellular Rejection in Renal Transplant Biopsies Following Campath-1H (Alemtuzumab) Induction Ann. Clin. Lab. Sci., January 1, 2007; 37(2): 121 - 126. [Abstract] [Full Text] [PDF] |
||||

